Synchronous Gastric Peritoneal CarcinomatosisFase 2NCT07475286
Combined Systemic and Intraperitoneal Chemotherapy for Synchronous Gastric and/or Gastroesophageal Peritoneal Carcinomatosis
Cisplatin, Mitomycin C
19 estudios de fase 2 reclutando ahora mismo, los actualizados más recientemente primero.
Abrir la página de fase 2 · una lista solo de esos estudios
Triangle is made by Triangle Health, Inc.
Estómago y esófago19 estudios
Synchronous Gastric Peritoneal CarcinomatosisFase 2NCT07475286
Cisplatin, Mitomycin C
Esophageal AdenocarcinomaFase 2NCT04682158
Carboplatin, 3 Dimensional Conformal Radiation Therapy, Propranolol, Intensity Modulated Radiation Therapy
Gastroesophageal AdenocarcinomaFase 2NCT07069712
Sonesitatug Vedotin, Rilvegostomig, Trastuzumab Deruxtecan (T-DXd), Capecitabine
Esophageal CancerFase 2NCT06123338
Pembrolizumab, Trastuzumab, Oxaliplatin, Capecitabine
Esophageal AdenocarcinomaFase 2NCT05563766Artículos
Itraconazole
Gastric AdenocarcinomaFase 2NCT06038578Artículos
TRK-950, Ramucirumab, Paclitaxel
Gastric AdenocarcinomaFase 2NCT03161522
Capecitabine, Chemotherapy, Conventional Surgery, Fluorouracil
Adenocarcinoma EsophagusFase 2NCT06044311
Vactosertib, Standard of Care Preoperative Therapy
Gastric CancerFase 2NCT06219941
AZD0901, 5-Fluorouracil, Leucovorin, l-leucovorin
Esophageal AdenocarcinomaFase 2NCT07603375
FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
Gastric CancerFase 2NCT07631000
Cadonilimab
Gastro-Intestinal CancerFase 2NCT05332002
Four week alternating FOLFOX and FOLFIRI (sFOLFOXIRI)
HER2-negativeFase 2NCT07546812
Denikitug, Nivolumab, Ramucirumab, Paclitaxel
Gastric CancerFase 2NCT04107077
Cisplatin, Mitomycin
Esophageal CarcinomaFase 2NCT07795749
Paclitaxel Q2W, Paclitaxcel Q3W
Stomach Cancer Stage IVFase 2NCT07070466
Ivonescimab, 5-Fluorouracil, Oxaliplatin, Leucovorin
Esophageal AdenocarcinomaFase 2NCT07222657Artículos
Standard of care chemotherapy, LNSC
Esophageal CancerFase 2NCT06906887
Induction Chemotherapy (modified FLOT or modified FOLFOX-6), Chemotherapy, Conventional Radiation, Pulsed Low-Dose-Rate (PLDR) Radiation
Esophageal AdenocarcinomaFase 2NCT04150640
Nal-IRI, Oxaliplatin, 5-FU, Trastuzumab